1. Home
  2. DMAC vs SDA Comparison

DMAC vs SDA Comparison

Compare DMAC & SDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DMAC
  • SDA
  • Stock Information
  • Founded
  • DMAC 2000
  • SDA 2007
  • Country
  • DMAC United States
  • SDA China
  • Employees
  • DMAC N/A
  • SDA N/A
  • Industry
  • DMAC Biotechnology: Pharmaceutical Preparations
  • SDA Blank Checks
  • Sector
  • DMAC Health Care
  • SDA Finance
  • Exchange
  • DMAC Nasdaq
  • SDA Nasdaq
  • Market Cap
  • DMAC 310.1M
  • SDA 266.9M
  • IPO Year
  • DMAC N/A
  • SDA N/A
  • Fundamental
  • Price
  • DMAC $6.97
  • SDA $2.65
  • Analyst Decision
  • DMAC Strong Buy
  • SDA Buy
  • Analyst Count
  • DMAC 3
  • SDA 1
  • Target Price
  • DMAC $12.33
  • SDA $3.50
  • AVG Volume (30 Days)
  • DMAC 443.2K
  • SDA 67.5K
  • Earning Date
  • DMAC 11-12-2025
  • SDA 09-12-2025
  • Dividend Yield
  • DMAC N/A
  • SDA N/A
  • EPS Growth
  • DMAC N/A
  • SDA N/A
  • EPS
  • DMAC N/A
  • SDA N/A
  • Revenue
  • DMAC N/A
  • SDA $458,905,000.00
  • Revenue This Year
  • DMAC N/A
  • SDA $20.77
  • Revenue Next Year
  • DMAC N/A
  • SDA $19.32
  • P/E Ratio
  • DMAC N/A
  • SDA N/A
  • Revenue Growth
  • DMAC N/A
  • SDA 24.15
  • 52 Week Low
  • DMAC $3.19
  • SDA $2.12
  • 52 Week High
  • DMAC $7.49
  • SDA $11.74
  • Technical
  • Relative Strength Index (RSI)
  • DMAC 66.23
  • SDA 57.19
  • Support Level
  • DMAC $6.83
  • SDA $2.60
  • Resistance Level
  • DMAC $7.41
  • SDA $2.82
  • Average True Range (ATR)
  • DMAC 0.42
  • SDA 0.20
  • MACD
  • DMAC 0.06
  • SDA 0.00
  • Stochastic Oscillator
  • DMAC 77.88
  • SDA 47.17

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

About SDA SunCar Technology Group Inc.

SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform.

Share on Social Networks: